Published • loading... • Updated
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
The biotech plans to use part of the proceeds for late-stage trials and further research as AbbVie takes a 4.9% stake.
Summary by WTVB
4 Articles
4 Articles
RNA drug developer ADARx seeks $1.74 billion valuation in US IPO - Regional Media News
Sept 21 (Reuters) - ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its US initial public offering, the company developing RNA drugs said on Monday. The company is aiming to raise up to $371.9 million by offering 21.9 million shares priced [...]
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
Sept 21 (Reuters) - ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in its U.S. initial public offering, the company said on Monday, as investor appetite for biotech listings strengthens. The San Diego, California -based company ...
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
